NDA 218549 · Alpha Cognition
Zunveyl
Benzgalantamine Gluconate · Oral
Last checked: Nov 19, 2026Latest source record: Jul 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jul 26, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
82
17 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 25, 2026.
ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults ( 1 )
Mechanism: Although the etiology of cognitive impairment in Alzheimer's disease (AD) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease. The degree of this cholinergic loss has been correlated with degree of cognitive impairment and density of amyloid plaques (a neuropathological hallmark of Alzheimer's disease). ZUNVEYL is a prodrug of galantamine. Galantamine, a tertiary alkaloid, is a competitive and reversible inhibitor of acetylcholinesterase. While the precise mechanism of galantamine's action is unknown,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 26, 2024 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form ReviewLetterLabel
3 products under this application
- ZUNVEYL · BENZGALANTAMINE GLUCONATE EQ 10MG BASE · TABLET, DELAYED RELEASE, ORAL · Prescription
- ZUNVEYL · BENZGALANTAMINE GLUCONATE EQ 15MG BASE · TABLET, DELAYED RELEASE, ORAL · Prescription
- ZUNVEYL · BENZGALANTAMINE GLUCONATE EQ 5MG BASE · TABLET, DELAYED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Benzgalantamine Gluconate" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- agitation7
- weight decreased7
- confusional state6
- somnolence6
- aggression5
- urinary tract infection5
- fall4
- pruritus4
- sedation4
- tremor4
- decreased appetite3
- gait disturbance3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 36 |
| 2026 | 46 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Alpha Cognition
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.